Skip to main content
Top
Published in: Pathology & Oncology Research 3/2017

01-07-2017 | Original Article

LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer via Regulation of Akt Signaling

Authors: Wei Peng, Zhuo Wang, Hong Fan

Published in: Pathology & Oncology Research | Issue 3/2017

Login to get access

Abstract

Long noncoding RNA (lncRNA) have been reported to modulate oncogenesis and be used to be target for tumor. The role of lncRNA NEAT1 (nuclear paraspeckle assembly transcript 1, Gene ID: 283131) in colorectal cancer (CRC) keeps unknown. This work was to investigate the pattern of lncRNA NEAT1 (NEAT1) expression in CRC and its functional value and biological significance. NEAT1 expression was analyzed in 56 cancer tissues and cell lines in CRC cases. Results showed that NEAT1 was significantly overexpressed in CRC cells and tissues. Clinicpathologic detection verified that high NEAT1 expression associated with bulk in CRC. The serum contents of NEAT1 were observably elevated comparing with healthy cases (P < 0.05). The levels of NEAT1 were elevated in distinguishing CRC from normal (ROCAUC = 0.9471; P < 0.01). Moreover, Kaplan–Meier analysis found that NEAT1 elevation led to adverse survival (P < 0.05). Further experiments illustrated that of NEAT1 knockdown signally inhibited growth and facilitated apoptosis. Importantly, we confirmed that Akt signaling pathway was inactivated after loss of NEAT1 in CRC. Taken together, this work support the first evidence that NEAT1 can be used to be a promising biomarker and target for novel treatment for human CRC.
Literature
1.
go back to reference Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365(9454):153–165CrossRefPubMed Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365(9454):153–165CrossRefPubMed
2.
go back to reference Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD (1997) A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 84(5):666–669CrossRefPubMed Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen OD (1997) A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 84(5):666–669CrossRefPubMed
3.
4.
go back to reference Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489–499CrossRefPubMed Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489–499CrossRefPubMed
6.
go back to reference Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136:629–641CrossRefPubMed Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136:629–641CrossRefPubMed
7.
go back to reference Peng W, Wu G, Fan H, Wu J, Feng J (2015) Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour biology: the journal of the international society for. Oncodevelopmental Biology and Medicine 36:6751–6758CrossRef Peng W, Wu G, Fan H, Wu J, Feng J (2015) Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. Tumour biology: the journal of the international society for. Oncodevelopmental Biology and Medicine 36:6751–6758CrossRef
8.
go back to reference Peng W, Fan H (2015) Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 72:113–118CrossRef Peng W, Fan H (2015) Long non-coding RNA PANDAR correlates with poor prognosis and promotes tumorigenesis in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 72:113–118CrossRef
9.
go back to reference Peng W, Feng J (2016) Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 77:65–71CrossRef Peng W, Feng J (2016) Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 77:65–71CrossRef
10.
go back to reference West JA, Davis CP, Sunwoo H, Simon MD, Sadreyev RI, Wang PI et al (2014) The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. Mol Cell 55:791–802CrossRefPubMedPubMedCentral West JA, Davis CP, Sunwoo H, Simon MD, Sadreyev RI, Wang PI et al (2014) The long noncoding RNAs NEAT1 and MALAT1 bind active chromatin sites. Mol Cell 55:791–802CrossRefPubMedPubMedCentral
11.
go back to reference Li Z, Liu YH, Diao HY, Ma J, Yao YL (2016) Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-met axis. Tumor Biol 37:673–683CrossRef Li Z, Liu YH, Diao HY, Ma J, Yao YL (2016) Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-met axis. Tumor Biol 37:673–683CrossRef
12.
go back to reference Zeng CW, Xu Y, Xu L, Yu XB, Cheng JJ, Yang LJ et al (2014) Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer 14:693CrossRefPubMedPubMedCentral Zeng CW, Xu Y, Xu L, Yu XB, Cheng JJ, Yang LJ et al (2014) Inhibition of long non-coding RNA NEAT1 impairs myeloid differentiation in acute promyelocytic leukemia cells. BMC Cancer 14:693CrossRefPubMedPubMedCentral
13.
go back to reference Wang P, Wu T, Zhou H, Jin Q, He G, Yu H et al (2016) Long noncoding RNA NEAT1 promotes laryngeal squamous cell cancer through regulating miR-107/CDK6 pathway. Journal of experimental & clinical cancer research: CR 35:22CrossRefPubMedCentral Wang P, Wu T, Zhou H, Jin Q, He G, Yu H et al (2016) Long noncoding RNA NEAT1 promotes laryngeal squamous cell cancer through regulating miR-107/CDK6 pathway. Journal of experimental & clinical cancer research: CR 35:22CrossRefPubMedCentral
14.
go back to reference Peng W, Zhang J, Liu J (2014) URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. Medical oncology (Northwood, London, England) 31:64CrossRef Peng W, Zhang J, Liu J (2014) URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. Medical oncology (Northwood, London, England) 31:64CrossRef
15.
go back to reference Peng W, Wu J, Feng J (2016) Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 79:188–193CrossRef Peng W, Wu J, Feng J (2016) Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 79:188–193CrossRef
16.
go back to reference Li X, Zhang Y, Cao S, Chen X, Lu Y, Jin H et al (2009) Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis. Int J Cancer 124:713–721CrossRefPubMed Li X, Zhang Y, Cao S, Chen X, Lu Y, Jin H et al (2009) Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis. Int J Cancer 124:713–721CrossRefPubMed
17.
go back to reference Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2:489–501CrossRefPubMed Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat Rev Cancer 2:489–501CrossRefPubMed
19.
20.
go back to reference Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61–66CrossRefPubMed Adams JM, Cory S (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 26:61–66CrossRefPubMed
21.
go back to reference Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM et al (2015) Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis 6:e1665CrossRefPubMedPubMedCentral Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM et al (2015) Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. Cell Death Dis 6:e1665CrossRefPubMedPubMedCentral
22.
go back to reference Peng W, Wu JZ, Feng JF (2016) Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomedicine & Pharmacotherapy 79:188–193CrossRef Peng W, Wu JZ, Feng JF (2016) Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomedicine & Pharmacotherapy 79:188–193CrossRef
23.
go back to reference Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464CrossRefPubMed Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24:7455–7464CrossRefPubMed
Metadata
Title
LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer via Regulation of Akt Signaling
Authors
Wei Peng
Zhuo Wang
Hong Fan
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2017
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0172-4

Other articles of this Issue 3/2017

Pathology & Oncology Research 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine